3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Breast Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
antineoplaston AS 2-1
3
antineoplaston A10
3
dactolisib
2
Temozolomide
2
Irinotecan
2
Everolimus
2
Bevacizumab
2
surufatinib
1
spartalizumab
1
poly ICLC
1
plerixafor
1
pasireotide
1
fosbretabulin
1
cixutumumab
1
adavosertib
1
Vaccines
1
TH 302
1
Sunitinib
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Radiation
1
PM 00104
1
Lapatinib
1
Immunologic Techniques
1
Immunoglobulin G
1
Genistein
1
Fentanyl
1
Donepezil
1
Disulfides
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neuroectodermal Tumors, Primitive
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts